Global pharmaceutical giants have unveiled over $160 billion in fresh U.S. investments within just the past few months. Thi...
Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,0...
DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU is the first trial in more than a decade to demonstrate superior eff...
Intuitive , a global leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS), announced the publication of two st...
Actum Pharma (Actum), a strategy and operating business partner to global biopharma manufacturers, today announces two executive appointments to launch a...
Innovative 6,000-square-foot facility enables clinical and commercial process development support to help cell therapy developers transition from researc...
The Trump administration has launched a bold and controversial national security investigation into America’s heavy reliance on impor...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered porta...
Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjug...
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show ...
Lonza joined CMAC to enhance its service offering for specialty and enhanced drug product and particle technologies Lonza will ser...
Mabion S.A. ("Mabion"), a leading Polish CDMO specializing in the development and manufacturing of biopharmaceuticals for third parties, and Instituto de B...
Enhancing high-quality logistics operations across the Americas, Asia Pacific, and EMEA to meet the evolving needs of the life sciences and healthcare ...
© 2025 Biopharma Boardroom. All Rights Reserved.
